Therapeutic strategies targeting interleukin-1 in vascular inflammation

Drug Discovery Today: Therapeutic Strategies

Volumn 3, Issue 3, 2006, Pages 367-373

  Adamson, Peter ^a,b  

^a Centre of Excellence for External Drug Discovery and Cardiovascular   (United Kingdom)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR;

BLOOD VESSEL; DRUG TARGETING; INFLAMMATION; ISCHEMIC HEART DISEASE; REVIEW; SIGNAL TRANSDUCTION;

EID: 33751233844     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2006.09.001     Document Type: Review

References (34)

1. Broody J.I., et al. Interleukin-1α as a factor in occlusive vascular disease. Am. J. Clin. Pathol. 97 (1992) 8-13
2. Ku G., et al. Induction of interleukin-1β expression from human peripheral blood monocyte-derived macrophages by 9-hydroxyoctadecadienoic acid. J. Biol. Chem. 267 (1992) 14183-14188
3. Thomas C.E., et al. Multiple lipid oxidation products in low density lipoproteins induce interleukin-1β release from human blood mononuclear cells. J. Lipid Res. 35 (1994) 417-427
4. Dinarello C.A. Biological basis for interleukin-1 in disease. Blood 87 (1996) 2095-2147
5. Filonzi E.L., et al. Cytokine regulation of granulocyte-macrophage colony stimulating factor production in human arterial smooth muscle. Atherosclerosis 99 (1993) 241-252
6. Maulik N., et al. Interleukin-1α pre-conditioning reduces myocardial ischemia reperfusion injury. Circulation 88 (1993) 387-394
7. Clausell N., et al. In vivo blockade of tumor necrosis factor-α in cholesterol fed rabbits after cardiac transplants inhibits acute coronary artery neointimal formation. Circulation 89 (1994) 2768-2779
8. Weckmann A.L., et al. Cytokine inhibitors in autoimmune disease. Semin. Arthritis Rheum. 26 (1996) 539-557
9. Dinarello C.A. Setting the cytokine trap for autoimmunity. Nat. Med. 9 (2003) 20-22
10. Preas H.L., et al. Effects of recombinant soluble type I interleukin-1 receptor on human inflammatory responses to endotoxin. Blood 88 (1996) 2465-2472
11. Fitzgerald A.A., et al. Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum. 52 (2005) 1794-1803
12. Pascual V., et al. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J. Exp. Med. 20 (2005) 1479-1486
13. Chevalier X., et al. Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: a multicenter study. J. Rheumatol. 32 (2005) 1317-1323
14. Kuida K., et al. Altered cytokine export and apoptosis in ice deficient in interleukin-1β converting enzyme. Science 267 (1995) 2000-2003
15. Li P., et al. Mice deficient in interleukin-1β converting enzyme (ICE) are defective in the production of mature interleukin-1β and resistant to endotoxic shock. Cell 80 (1995) 401-411
16. Ferrari, et al. The P2X7 receptor: A key player in IL-1 processing and release. J. Immunol. 176 (2006) 3877-3883
17. Ralevic V., et al. Receptors for purines and pyrimidines. Pharmacol. Rev. 50 (1998) 413-492
18. 496 to Ala polymorphism in the P2X7 receptor impairs ATP-induced IL-1β release from human monocytes. J. Immunol. 172 (2004) 3399-3405
19. Griffiths R.J., et al. ATP-induces the release of IL-1 from LPS-primed cells in vivo. J. Immunol. 154 (1995) 2821-2828
20. Ferrari D., et al. Extracellular ATP triggers IL-1β release by activating the purinergic P2Z receptor on human macrophages. J. Immunol. 159 (1997) 1451-1458
21. 357 to Ser polymorphism in homozygous and compound heterozygous subjects causes absent or reduced P2X7 function and impairs ATP-induced mycobacterial killing by macrophages. J. Biol. Chem. 281 (2005) 2079-2086
22. Labasi J.M., et al. Absence of the P2X7 receptor alters leukocyte function and attenuates an inflammatory response. J. Immunol. 168 (2002) 6436-6445
23. Chessell, I.P. et al. (2005) Disruption of the P2X7 purioreceptor gene abolishes chronic inflammatory and Neuropathic pain. Pain 114, 386-396
24. 7 receptor activation. J. Immunol. 173 (2004) 1202-1208
25. Lee J.C., et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372 (1994) 739-746
26. Dinarello, C.A. Role of eukaryotic translation initiation factors 5A in acute lung injury. 10th International Inflammation and Immune Disease Drug Discovery & Development World Summit, 20-21 March 2006, New Brunswick, NJ, USA
27. Suzuki N., et al. Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4. Nature 416 (2002) 750-756
28. Medvadev A.E. Distinct mutations in IRAK-4 confer hypo-responsiveness to lipopolysaccharide and interleukin-1 in a patient with recurrent bacterial infections. J. Exp. Med. 198 (2003) 521-531
29. Huang Y., et al. IRAK1 serves as a novel regulator essential for lipopolysaccharide-induced interleukin-10 gene expression. J. Biol. Chem. 279 (2004) 51697-51703
30. Greenwood J., et al. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat. Rev. Immunol. 6 (2006) 358-370
31. Opal S.M., et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit. Care Med. 25 (1997) 1115-1124
32. Nuki G., et al. Long term safety and maintenance of clinical improvement following treatment with anakinara (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extention of a randomised double-blind placebo-controlled trail. Arthritis Rheum. 46 (2002) 2823-2846
33. Jones, J. et al. (2006) A novel caspase inhibitor VX-166 reduces myocardial infarction in the rat. J. Am. Coll. Cardiol. (Suppl.) 47 (Abstract 170)
34. Godfrey C., et al. The pharmacokinetics (PK) and pharmacodynamics (PD) of VX-702, a novel, oral p38MAPK inhibitor in healthy volunteers. Clin. Pharmacol. Ther. 75 (2004) (Abstract 52)